Abstract
The synthesis and characterization of two new pyran derivatives (1 and 2) are characterized by infrared (IR) and 1H nuclear magnetic resonance spectroscopy (1H NMR), high resolution mass spectrum (HRMS), and single crystal X-ray crystallography. The anticancer activity of compounds is investigated against four human liver cancer cells (Hep G2, SMMC-7721, HHCC, and HB611) by 3-(4,5)-dimethylthiahiazo(-z-y1)-3,5-di-phenytetrazoliumbromide (MTT) assay. Furthermore, molecular docking studies support the biological assay data and suggest that the two compounds have a similar interaction strength with protein.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
